LIBOICO, officially known as Lisa Pharma, is a prominent player in the pharmaceutical industry, headquartered in Italy. Founded in 2001, the company has established itself as a leader in the development and distribution of innovative healthcare solutions, primarily focusing on prescription medications and over-the-counter products. With a strong operational presence across Europe and beyond, LIBOICO is recognised for its commitment to quality and efficacy. The company’s core offerings include a diverse range of pharmaceutical products that cater to various therapeutic areas, setting them apart through rigorous research and development processes. Notable achievements include significant partnerships and a growing portfolio that underscores LIBOICO's market position as a trusted name in healthcare. With a focus on patient-centric solutions, LIBOICO continues to drive advancements in the pharmaceutical sector.
How does LIBOICO's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
LIBOICO's score of 8 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
LIBOICO, headquartered in Italy, currently does not report any carbon emissions data, as there are no available figures for kg CO2e emissions. Additionally, the company has not established specific reduction targets or initiatives related to climate commitments. Without emissions data or defined climate strategies, LIBOICO's position in the context of industry climate action remains unclear. The absence of reported emissions and commitments highlights a potential area for improvement in transparency and accountability regarding environmental impact.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
LIBOICO has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
